• CLEVELAND, OHIO
  • 1-866-UH4-CARE
  • |
  • Search UH Online
Patients & Visitors Clinical Trials Listing
Print this pageEmail this pageBookmark Page

In This Section

Contact Information

General Phone Number
888-844-8447
216-844-8447
Mailing Address
11100 Euclid Avenue
Cleveland, OH 44106
Clinical Trials

Trial Name:

CASE 2204
Intro: A Phase IB Study in Patients with Metastatic Colorectal Cancer to Evaluate Pharmacodynamic Effects of Erlotinib and Safety and Efficacy of Erlotinib in Combination with modified FOLFOX6 (mFOLFOX6) and Beracizumab.
Condition:
Description: This is study is being done to characterize the inhibition of pEGFR (epidermal growth factor receptor) after treatment with oral Erlotinib daily in patients with metastatic colorectal cancer. Modified FOLFOX 6 chemotherapy (oxaliplatin, 5-fluororuacil, and leucovorin) begins in cycle 2 or 3 depending on the dose of Erlotinib tolerated by patient. Patients will continue in the study until disease progression, intolerance of side effects, or withdrawal of consent.
Criteria:
  1. Patients must have histologically proven metastatic colorectal cancer
  2. Patients must have recovered from the side effects of cytotoxic chemotherapy, radiation treatment and/or major surgery that could interfere with protocol therapy
  3. Patients must have a life expectancy of at least 3 months.
Contact: For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422

Participant Confidentiality:

All information regarding participation in Clinical Trials is treated with the utmost confidentiality. University Hospitals Case Medical Center and the Division of Clinical Research recognize and respect the confidentiality of this information. Access to information related to clinical trials and their participants is restricted to authorized clinical trials personnel only.

Back